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http:WHAT THIS PAPER ADDS
This study demonstrates that simvastatin exerts different effects on the matrix metalloproteinases (MMPs),
binding protein and tissue inhibitors of MMPs (TIMPS), and neutrophil gelatinase-associated lipocalin in aortic
aneurysms and intraluminal thrombi (ILTs). It is proposed that simvastatin may differently inﬂuence the gene
and protein content of TIMPs in aneurysmal walls and ILTs.Objective/Background: Matrix metalloproteinases (MMPs) play a pivotal role in the development and
progression of abdominal aortic aneurysms (AAAs). The action of MMPs depends on a balance between tissue
inhibitors of MMPs (TIMPs) and compounds that may prolong protease activity, such as neutrophil gelatinase-
associated lipocalin (NGAL).
Methods: The study was designed to analyse gene expression and protein concentration of MMPs, TIMPs, and
NGAL in AAA walls and intraluminal thrombi (ILTs) of patients on simvastatin (n ¼ 10) and not on statins (n ¼ 10).
The patients were matched by age, sex, and AAA diameter. Expression of MMP2, MMP9, TIMP1, TIMP2, and
NGAL was investigated by real time polymerase chain reaction, and MMP2, MMP9, MMP9/TIMP1, MMP9/
TIMP2, and MMP9/NGAL protein levels by enzyme-linked immunosorbent assay.
Results: MMP2 and MMP9 protein and mRNA levels were comparable in the simvastatin and non-statin groups
(p > .05); however, there was a signiﬁcant decrease in TIMP1 mRNA in AAA tissue (p ¼ .04). Moreover, a
signiﬁcant increase in MMP9/TIMP2 complex concentration in ILTs of patients on simvastatin was noted (median
94.71 ng/mL in the simvastatin group vs. 36.80 ng/mL in the non-statin group; p ¼ .01). No signiﬁcant difference
was observed for NGAL mRNA or protein content in AAA and ILT.
Conclusion: Simvastatin treatment in patients with AAAs may inﬂuence the concentration of proteases and their
inhibitors (TIMPs) in aneurysmal wall tissue and ILTs. Thus, further studies should be undertaken to understand
the different inﬂuence of statin therapy on the components of the MMP/TIMP system in AAAs and ILTs.
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An abdominal aortic aneurysm (AAA) is a dilatation of the
aorta frequently associated with an atherosclerotic back-
ground that occurs in around 6% of men aged between 65
and 85 years.1,2 AAAs are also a cause of 1e3% of all deaths
worldwide, mostly induced by AAA rupture; the probability
of rupture rises when the AAA reaches a diameter of
>5.5 cm.3 However, unlike atherosclerotic occlusiverresponding author.
il address: ihor.huk@meduniwien.ac.at (I. Huk).
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//dx.doi.org/10.1016/j.ejvs.2015.02.011disease, the development of an AAA is not a lipid driven
pathology, which allows more precise evaluation of the
potential anti-inﬂammatory and extracellular matrix-
modulating effects of statins (hydroxymethylglutaryl-coen-
zyme A reductase inhibitors). It has been found previously
that statins may reduce AAA growth rates and rupture risk
by stabilizing endothelial function and attenuating oxidative
stress and inﬂammation in the vascular wall.4e7
The development and progression of AAAs is substan-
tially mediated by matrix metalloproteinases (MMPs), the
activity of which is under the control of tissue inhibitors of
MMP (TIMPs) and neutrophil gelatinase-associated lipocalin
(NGAL).8 In general, the action of MMPs is inhibited when
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to NGAL. Therefore, drugs that inﬂuence the concentration
of MMPs, TIMPs, or NGAL, as well as the level of MMP/
TIMP and MMP/NGAL complexes, may modulate the pro-
gression of AAAs and intraluminal thrombus (ILT) formation.
MMP2 and MMP9, with their elastolytic activity, have been
shown to be involved in aneurysm formation.6,9 The main
sources of MMP9 are inﬁltrating macrophages that can also
produce NGAL.10e12 Recently, Serra et al. presented data
that plasma MMP9 and NGAL levels were signiﬁcantly
elevated in cerebral artery aneurysm patients,13 while
Zografos et al. described a signiﬁcant increase in plasma
NGAL in patients with coronary artery disease.14
AAAs >45 mm often contain ILTs, which it is speculated
are the main source of proteolytic compounds that may
inﬂuence aortic wall degradation.10,15,16 Recent studies
found that ILT thickness is associated with the apoptosis of
vascular smooth muscle cells, and elastin degradation cor-
relates positively with MMP2, active MMP9, and TIMP1
concentrations in the adjacent AAA wall.11,15,17,18
However, the inﬂuence of simvastatin therapy on protease
activity after creating a complex with TIMPs or NGAL in AAAs
and ILTs is not known. Therefore, this study investigates
whether simvastatin treatment in patients undergoing AAA
repair inﬂuences MMP2, MMP9, TIMP1, TIMP2, and NGAL
mRNA and protein levels in aneurysmal walls and ILTs.
MATERIAL AND METHODS
Patients
Ninety-eight patients were enrolled in the study and un-
derwent open AAA repair between September 2009 and
December 2011 at the Department of Surgery, Medical
University of Vienna, according to a previous study.5
From that cohort, patients from whom both ILT and AAA
wall samples were available were chosen; next, only those
who were on simvastatin or who had taken no statins for at
least 6 months before the AAA repair were selected. From
that group, age matched patients with comparable AAA di-
ameters were chosen. Finally, 10 “non-statin” patients and
10 patients receiving simvastatin were chosen to study the
effects of statins on inﬂammatory and proteolytic markers in
AAA and ILT. Exclusion criteria included the intake of statins
other than simvastatin; non-steroidal anti-inﬂammatory
drugs, except aspirin in the medication list; chronic diseases
such as liver diseases; inﬂammatory diseases; malignant
diseases; recreational drug intake; and alcohol abuse. After
obtaining written informed consent, patient data were pro-
spectively collected, and aneurysm wall tissue was harvested
during surgery for retrospective analysis. Patients were
matched in a 1 (simvastatin) to 1 (non-statin) ratio by age,
sex, and AAA diameter (in the listed order). Ten non-statin
patients (eight men, two women) were included in the
control group and 10 patients who had received simvastatin
(seven men, three women) in their medical history (20e
40 mg daily for a minimum of 6 months) were included to
the simvastatin group. AAA diameter was measured with
pre-operative computed tomography angiography.The study was approved by the local institutional ethics
committee (EC 294/2009) at the Medical University of
Vienna.
Tissue harvesting
After aortic cross clamping and longitudinal incision of the
aneurysm, thrombus samples (in proximity with the aortic
side wall) were collected, and the rest of the thrombus was
removed, and about 3 cm2 of the aneurysm sack at the site
of its maximum diameter was excised. Aneurysm and
thrombus samples were immediately frozen in liquid ni-
trogen and stored at 80 C. For subsequent analysis,
aneurysmal tissue and thrombi were processed on ice.
Aneurysmal wall and thrombi were divided into 50 mg
pieces, and rinsed with ice cold saline to eliminate liquid
components such as blood and residual thrombi.
Enzyme linked immuno-enzymatic assays for MMP2,
MMP9, MMP9/TIMP1, MMP9/TIMP2, and MMP9/NGAL
A total of 50 mg of frozen aortic wall or thrombus tissue was
ground in 4-(2-hydroxyethyl)-1-piperazineethanesulfonic
acid (HEPES) buffer (20 mM HEPES [pH 7.6], 1.5 mM ethyl-
enediaminetetraacetic acid, 0.5 mM benzamidine and
enzyme inhibitors; all from SigmaeAldrich, St Louis, MO,
USA). After centrifugation (30,000  g at 4 C for 20 mi-
nutes), the supernatant was collected for protein assay,
which was performed using the Bradford reagent (Sigmae
Aldrich). A total of 100 ml of homogenate with equal protein
content (diluted with sample diluents provided by the
manufacturer) was loaded on enzyme linked immunosor-
bent (ELISA) plate wells. The MMP2, MMP9, MMP9/TIMP1,
MMP9/TIMP2, and MMP9/NGAL levels were quantiﬁed us-
ing speciﬁc ELISAs (R&D Systems, Minneapolis, MN, USA).
The MMP2 level was assayed with the DuoSet kit (catalogue
no. DY902; range 0.625e20.000 ng/mL, speciﬁcity for active
and prorecombinant human [rh] MMP2 but not for rhMMP2
complexed to rhTIMP2drhTIMP-2 does not cross react in
this assay but does interfere at concentrations > 1.56 ng/
mL). The MMP9 kit (catalogue no. DY911) had a range of
31.2e2,000.0 pg/mL, and measures the 92-kDa, pro-MMP9
and the 82-kDa active MMP9. It does not measure the 65-
kDa form and it does not cross react with recombinant
human TIMP1 but it may interfere at concentrations
>1.56 ng/mL. The MMP9/TIMP1 level was determined with
a kit (catalogue no. DY1449), the range of which was 46.9e
3,000.0 pg/mL (speciﬁcity: no interferences declared). The
MMP9/TIMP2 level was measured with a kit (catalogue no.
DY1453), the range of which is 0.391e25.000 ng/mL
(speciﬁcity for MMP9/TIMP2); the kit does not interference
with MMP9/TIMP1 or MMP9/TIMP3 when at a
concentration < 25 ng/mL, or with MMP9/TIMP4 when at
concentration < 50 ng/mL. The MMP9/NGAL level was
assayed with a kit (catalogue no. DM9L20), the range of
which is 0.312e20.000 ng/mL (sensitivity is 0.058 ng/mL,
and speciﬁcity for natural and recombinant MMP9/NGAL).
Absorption was read at 450 nm (ELx800 absorbance reader;
BioTek, Winooski, VT, USA). Values were expressed as pg/mL
Table 1. Patient characteristics.
Non-statin
(n ¼ 10)
Simvastatin
(n ¼ 10)
p
Age (years) 65 (54e73) 64 (61e78) .85
AAA diameter
(mm) (range)
56.0
(48.0e102.0)
55.5
(50.0e112.0)
.17
BMI (kg/m2) 28 (22e38) 26 (24e28) .08
Coronary artery
disease (n)
2 2 .56
Cerebrovascular
artery disease (n)
5 6 .56
Diabetes (n) 3 3 1.00
Cardiac
insufﬁciency (n)
1 2 .56
Nicotine (n) 7 7 1.00
Peripheral artery
disease (n)
3 3 1.00
CRP (mg/dL) 1.03 (0.03e7.60) 0.70 (0.06e3.00) .85
Cholesterol
(mg/dL)
233.5
(187.0e323.0)
200.0
(110.0e228.0)
.05
HDL (mg/dL) 45.0 (36.0e68.0) 45.5 (29.0e57.0) .54
LDL (mg/dL) 167.2
(93.0e218.0)
132.5
(56.0e218.0)
.27
Creatinine
(mg/dL)
0.96 (0.75e1.36) 1.05 (0.9e4.0) .24
Haemoglobin
(g/dL)
13.1 (11.9e16.0) 14.3 (12.0e16.5) .32
Leucocytes
(106/mL)
8.3 (5.5e12.0) 8.5 (5.3e13.0) .77
Fibrinogen
(mg/dL)
445.5
(280.0e594.0)
450.0
(280.0e549.0)
.52
Note. Data are given as median (range) unless otherwise stated.
Signiﬁcance for binary variables was assessed using McNemar’s
rank test models, while metric values were analysed using
Wilcoxon’s signed rank test. AAA ¼ abdominal aortic aneurysm,
BMI ¼ body mass index; CRP ¼ C reactive protein; HDL ¼ high
density lipoprotein; LDL ¼ low density lipoprotein.
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samples 1:2 (v:v) dilutions were made. Assays were per-
formed in duplicate and repeated twice with three different
tissue pieces from each patient.
Real time quantitative polymerase chain reaction for
MMP2, MMP9, NGAL, TIMP1 and TIMP2
Frozen tissue was homogenized using a ball mill (Retsch,
Haan, Germany), and mRNA was isolated using the High
Pure RNA Tissue Kit (Roche, Basel, Switzerland). Reverse
transcription was performed using Transcriptor First Strand
cDNA Synthesis Kit (Roche). Real time polymerase chain
reaction was performed using a LightCycler TaqMan
Master mix (Roche) according to the manufacturer’s in-
structions. Primers (forward [fwd] and reverse [rev]) were
designed using the Roche Universal ProbeLibrary Assay
Design Centre: glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) (fwd: AGCCACATCGCTCAGACAC; rev: GCCCAA-
TACGACCAAATCC); NGAL (fwd: CAGGACTCCACCTCAGACCT;
rev: CCAGGCCTACCACATACCAC); MMP9 (fwd: GAACCAATC-
TCACCGACAGG; rev: GCCACCCGAGTGTAACCATA); MMP2
(fwd: ATAACCTGGATGCCGTCGT; rev: AGGCACCCTTGAA-
GAAGTAGC); TIMP1 (fwd: GGGCTTCACCAAGACCTACA; rev:
TGCAGGGGATGGATAAACAG); TIMP2 (fwd: GAAGAGCCTGA-
ACCACAGGT; rev: CGGGGAGGAGATGTAGCAC). The ampliﬁ-
cation conditions consisted of an initial incubation at 95 C
for 10 minutes, followed by 45 cycles of 95 C for 10 sec-
onds, 63 C for 20 seconds, 72 C for 6 seconds, and a ﬁnal
cooling to 4 C. GAPDH, as a housekeeping gene, was a
reference gene for all analysed genes of interest. To quantify
gene expression, the quantiﬁcation cycle (Cq) for an RNA
from the gene of interest was subtracted from the Cq of
RNA from a GAPDH in the same sample to adjust for vari-
ation in the amount and quality of RNA between different
samples. Data were analysed using LightCycler Software
Version 3.5 (Roche).
Statistical analysis
Continuous demographic and biochemical data are pre-
sented as median, minimum, and maximum; and de-
mographic categorical data are described with absolute
frequencies and percentages. Data are 1:1 matched in the
simvastatin and non-statin groups, and group differences
were tested by Wilcoxon’s signed rank test for continuous
data and by McNemar’s test for binary data. A generalized
linear model (binomial, logit) with an exchangeable cor-
relation matrix was used to analyse matched binary
outcome data, including sex, age, and aneurysm diameter.
A linear mixed model with a compound symmetry vari-
anceecovariance matrix was used to analyse matched
continuous outcome data, also including sex, age, and
aneurysm diameter. In case of skew residuals a logarith-
mic transformation usually led to normally distributed
errors.
All p-values are two sided and p  .05 was considered
signiﬁcant. Statistical analyses were performed with SAS
(version 9.3; SAS Institute Inc., Cary, NC, USA).RESULTS
Patient characteristics
The characteristics for non-statin and simvastatin treated
patients are presented in Table 1. The two groups were
comparable with regard to age, aneurysm diameter,
comorbidities, and risk factors. The median aneurysm
diameter was 56.0 mm (range 48.0e102.0 mm) for the non-
statin group and 55.5 mm (50.0e112.0 mm) for the sim-
vastatin group (p ¼ .17). Patients in the simvastatin group
had a tendency to have lower body mass index (median 26
vs. 28 kg/m2; p ¼ .08) and had a signiﬁcantly lower total
cholesterol level (median 200 vs. 230 mg/dL; p ¼ .05). No
signiﬁcant differences in C reactive protein, ﬁbrinogen,
creatinine levels, or haemoglobin and leucocyte counts
among the two groups were noted (all p  .10).
Simvastatin treatment inﬂuences TIMP1 mRNA in AAAs,
MMP9/TIMP2 protein level in ILTs, and NGAL mRNA in the
ILT and AAA samples
The MMP9 protein level was signiﬁcantly higher in ILTs than
in AAAs (p < .01), and the mean MMP9 content was
552 A. Piechota-Polanczyk et al.3.58 ng/mL and 0.14 ng/mL in non-statin and simvastatin
groups, respectively (Fig. 1). Conversely, a tendency towards
a lower level of MMP2 protein in ILTs than in AAA wall
tissue (median 0.002 ng/mL vs. 1.81 ng/mL in the non-
statin vs. simvastatin groups; p < .01) (Fig. 2) was
observed. The tendency was not inﬂuenced by simvastatin.
Although MMP2 and MMP9 protein and gene expression
levels were comparable in the simvastatin and non-statin
groups (p > .05), signiﬁcant (p ¼ .04) downregulation of
TIMP1 mRNA after simvastatin medication in AAA walls was
observed. The overall concentration of TIMP1 mRNA was
markedly lower in ILTs compared with AAAs (Fig. 3).
Moreover, the concentration of the MMP9/TIMP2 complex
was signiﬁcantly lower in AAAs than in ILTs (p < 0.01;
Fig. 4). A signiﬁcant increase in MMP9/TIMP2 complex
concentration in ILTs of simvastatin treated patients was
detected (median 94.71 ng/mL in simvastatin group vs.
36.80 ng/mL in non-statin group; p ¼ .01 [Table 2]).
These results may indicate a different expression of
TIMP1 in AAA walls and MMP9/TIMP2 in ILTs under sim-
vastatin treatment.
NGAL protein complexed with MMP9 is responsible for
the prolongation of action of MMP9. In this study NGAL
mRNA levels were comparable in ILTs of simvastatin treated
group with ILTs of non-statin patients (p ¼ .49), and sim-
vastatin also had no inﬂuence on MMP9/NGAL protein
content in both ILTs or AAA walls (p > .05) (Table 2).DISCUSSION
The results of this study show that simvastatin treatment in
patients with AAAs has little inﬂuence on MMP2 and MMP9
concentrations in the aneurysmal walls or ILTs. However,
MMP2 expression and protein concentration seem to be
decreased in ILTs compared with aneurysmal walls, while, in
these patients, MMP9 protein is upregulated in ILTs
compared with AAA walls. As the concentrations of MMPs
are elevated in AAA tissue compared with normal aortic
walls, many researchers focus on the role of proteases inFigure 1. The changes in matrix metalloproteinase 9 (MMP) protein
thrombus (ILT) in the non-statin (n ¼ 10) and simvastatin groups (n ¼
rank test. A linear mixed model with a compound symmetry varian
outcome data. The data are presented as mean  SD.AAA aetiology.16 Previously, it has been suggested that
simvastatin decreases tissue MMP2 and MMP9 levels in
animal models of AAA.19 Moreover, a small randomized trial
showed less total and active MMP9 in AAA patients pre-
scribed simvastatin compared with a placebo group.17
However, in humans, statin treatment induced a trend to-
wards higher concentration of active MMP2 but not MMP9
in AAA tissue.20 Furthermore, the content of serum MMP2
and MMP9 in patients with AAAs was not correlated with
statin therapy.21
In the aneurysm wall, MMPs have a different origin.
MMP2 derives from smooth muscle cells, while MMP9 is
produced by activated macrophages.22,23 In this study,
MMP2 content was signiﬁcantly higher in AAA wall samples
than in ILTs, which is in contrast to MMP2, which was greater
in ILTs than AAA walls. Those observations conﬁrm that ILT is
a place of ongoing inﬂammation and a source of proteolytic
proteases that may lead to further AAA progression.23
Protease activity is under the control of TIMPs. In this
study signiﬁcant differences were observed in TIMP1
expression in AAA walls and MMP9/TIMP2 complex in ILTs
after simvastatin treatment. The expression of TIMP1 was
downregulated only in AAA tissue; while MMP9/TIMP2
complex was signiﬁcantly upregulated in ILT after simva-
statin treatment. The higher content of MMP9/TIMP1 in
ILTs in patients on simvastatin may indicate the protective
role of statins in AAA progression as MMP9 is mostly
generated by activated macrophages and may be consid-
ered a marker of ongoing inﬂammation in ILTs.2 An increase
in MMP9/TIMP2 complex after simvastatin may inﬂuence
the process of AAA progression by inhibiting the degrada-
tion of elastic ﬁbres, which may be another protective
mechanism of simvastatin in patients with AAAs.4,5 How-
ever, this needs to be further conﬁrmed.
Previous studies have shown that MMP9 and TIMP1, as
well as MMP2 and TIMP2, correlate with ILT thickness in
patients with AAA.15,24 Recently, it was found that mono-
cytes, the numbers of which are increased during aneurysm
formation, act on endothelium leading to elevation oflevel in abdominal aortic aneurysm (AAA) wall and intraluminal
10). Statistical signiﬁcance was calculated with Wilcoxon’s signed
ceecovariance matrix was used to analyse matched continuous
Figure 2. The change of matrix metalloproteinase 2 (MMP) protein level in abdominal aortic aneurysm (AAA) wall and intraluminal
thrombus (ILT) in the non-statin (n ¼ 10) and simvastatin (n ¼ 10) groups. Statistical signiﬁcance was calculated with Wilcoxon’s signed
rank test. A linear mixed model with a compound symmetry varianceecovariance matrix was used to analyse matched continuous
outcome data. The data are presented as mean  SD.
Figure 3. The changes in TIMP1 mRNA in abdominal aortic aneurysm (AAA) wall and intraluminal thrombus (ILT) in the non-statin (n ¼ 10)
and simvastatin (n ¼ 10) groups. Statistical signiﬁcance was calculated with Wilcoxon’s signed rank test. A linear mixed model with a
compound symmetry varianceecovariance matrix was used to analyse matched continuous outcome data. The data are presented as
mean  SD. Note. TIMP1 ¼ tissue inhibitor of matrix metalloproteinase 1; GAPDH ¼ glyceraldehyde 3-phosphate dehydrogenase.
Human Intraluminal Thrombus and Abdominal Aortic Aneurysm Tissue 553MMP9 in patients with AAAs.8,25 Furthermore, Kajimoto
et al. indicated that statin treatment reduces the expression
of Janus kinases in AAA wall and dendritic cell activity, which
are a source of proteases, including MMP9 and MMP2.25Figure 4. The changes in matrix metalloproteinase (MMP9)/tissue in
aneurysm (AAA) wall and intraluminal thrombus (ILT) in the non-statin (
calculated with Wilcoxon’s signed rank test. A linear mixed model with
analyse matched continuous outcome data. The data are presented asSimilarly, in a previous study, it was shown that simva-
statin decreased pro-inﬂammatory nuclear factor-kB (NF-kB)
and extracellular regulated kinase (ERK) signalling pathways
activity in aneurysmal wall.4,5 It was documented thathibitor of matrix metalloproteinase (TIMP)2 in abdominal aortic
n¼ 10) and simvastatin (n¼ 10) groups. Statistical signiﬁcance was
a compound symmetry varianceecovariance matrix was used to
mean  SD.
Table 2. Analysed parameters in abdominal aortic aneurysms (AAA) and intraluminal thrombi (ILT) in the non-statin and simvastatin
groups.
AAA wall ILT
Non-statin (n ¼ 10) Simvastatin (n ¼ 10) p Non-statin (n ¼ 10) Simvastatin (n ¼ 10) p
Mean MMP2/GAPDH
mRNA (range)
0.43 (0.02e3.27) 0.42 (0.08e1.00) .82 0.46 (0.01e1.52) 0.12 (0.01e1.13) .38
MMP2 (ng/mL) 1.81 (0.93e12.4) 1.70 (0.67e7.77) .85 0.0020 (0.0003e0.0090) 0.0030 (0.0006e0.0400) .53
MMP9/GAPDH mRNA 0.61 (0.08e5.50) 0.84 (0.04e2.27) .82 0.71 (0.05e4.00) 0.450 (0.002e5.160) .51
MMP9 (ng/mL) 0.14 (0.05e0.34) 0.170 (0.056e0.589) .31 3.58 (0.59e13.95) 5.03 (0.34e11.47) .25
NGAL/GAPDH mRNA 0.92 (0.03e9.48) 1.22 (0.03e4.20) .78 0.29 (0.02e23.44) 2.940 (0.005e7.810) .49
MMP9/NGAL (pg/mL) 0.54 (0.02e3.69) 0.84 (0.19e1.88) .33 0.46 (0.03e4.28) 0.28 (0.02e1.18) .47
TIMP1/GAPDH mRNA 1.45 (0.35e10.35) 0.59 (0.01e6.36) .04 0.27 (0.03e0.56) 0.06 (0.03e1.34) .13
MMP9/TIMP1
(pg/mL in AAA;
ng/mL in ILT)
163.35 (3.04e319.43) 184.19 (9.12e394.51) .40 0.27 (0.04e0.77) 0.230 (0.001e2.420) .52
TIMP2/GAPDH mRNA 1.02 (0.26e1.75) 1.35 (0.57e2.88) .13 1.24 (0.40e2.86) 2.60 (0.51e10.48) .12
MMP9/TIMP2 (ng/mL) 0.26 (0.12e1.22) 0.31 (0.10e1.16) .43 36.80 (12.78e86.77) 94.71 (23.89e275.27) .01
Note. Data are given as median (range) unless otherwise speciﬁed. MMP ¼ matrix metalloproteinase; GAPDH ¼ glyceraldehyde 3-
phosphate dehydrogenase; TIMP ¼ tissue inhibitor of matrix metalloproteinase; NGAL ¼ neutrophil gelatinase-associated lipocalin-2.
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ated with increased activity of MMP2 and MMP9 in vascular
smooth muscle cells and in aneurysmal tissue during AAA
progression.26,27 The increased activity of pro-inﬂammatory
signalling pathways and protease activity in aneurysmal
wall may, in turn, inﬂuence thrombus formation.
Another protein that inﬂuences the activity of MMPs is
NGAL. In this study we noticed that NGAL mRNA but not
MMP9/NGAL complex has a tendency towards higher values
after simvastatin treatment in patients with ILTs. NGAL exists
in monomeric and homo- and hetero-dimeric forms, the
latter as a dimer with MMP9.28 Approximately 50% of the
NGALegelatinase complex isolated from human neutrophils
exists in a ternary complex with TIMP1.29 A previous report
showed that the expression of NGAL was associated with
MMP9 in the luminal part of AAA tissue,8 and that NGAL is
released by circulating polymorphonuclear cells and ILTs in
patients with AAAs.30 Furthermore, high expression of NGAL
has been shown in atherosclerotic human plaques associ-
ated with upregulated MMP9 activity.31 Therefore, NGAL
and MMP9/NGAL may be involved in AAA formation.
Although this study indicates that TIMP1 mRNA is
downregulated in aortic wall samples taken from patients
on simvastatin, and that the amount of MMP9/TIMP2
protein complex is increased in ILT samples from patients on
simvastatin, it has some limitations. Firstly, the study was
conducted on a limited number of samples, which may in-
ﬂuence the signiﬁcance of the results. Moreover, no
decrease in low density lipoprotein cholesterol was
observed in the statin group. In two previous papers on the
effects of simvastatin on oxidative stress parameters and
pro-inﬂammatory signalling pathways and cytokines, the
stimvastatin group had signiﬁcantly reduced different
oxidative stress parameters (NF-kB and ERK signalling
pathways activity, and pro-inﬂammatory molecules like
cyclophilin A and tumour necrosis factor-a).4,5 However,
further studies are necessary to prove the concept of
different proteases and the activities of their inhibitors in
AAAs and ILTs in patients receiving statin treatment.In conclusion, the present study indicates that proteases
are differently expressed in aneurysmal tissue and ILTs of
patients with AAAs, and that simvastatin therapy has little
inﬂuence on MMP2 and MMP9 levels. However, patients
with AAAs treated with simvastatin seemed to have
downregulated gene expression of TIMP1 in the AAA wall
and upregulated MMP9/TIMP2 complex in ILTs. There were
few changes in TIMP2 mRNA and MMP9/TIMP2 complex in
ILTs. No changes in the expression of NGAL mRNA or the
protein concentration of MMP9/NGAL are apparent in ILTs
after simvastatin treatment.
Therefore, simvastatin treatment in patients with AAAs
may differently inﬂuence the activity of proteases and their
inhibitors (TIMPs) in aneurysmal walls and ILTs. However,
further analysis is needed to verify those ﬁndings.CONFLICT OF INTEREST
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